$41.6 M

NAVB Mkt cap, 20-Sep-2018

$818.6 K

Navidea Biopharmaceuticals Revenue Q2, 2018
Navidea Biopharmaceuticals Gross profit (Q2, 2018)782.9 K
Navidea Biopharmaceuticals Gross profit margin (Q2, 2018), %95.6%
Navidea Biopharmaceuticals Net income (Q2, 2018)-9.1 M
Navidea Biopharmaceuticals EBIT (Q2, 2018)-4.9 M
Navidea Biopharmaceuticals Cash, 30-Jun-20184.7 M
Navidea Biopharmaceuticals EV41.3 M

Navidea Biopharmaceuticals Revenue

Navidea Biopharmaceuticals revenue was $1.81 m in FY, 2017

Embed Graph

Navidea Biopharmaceuticals Income Statement

Annual

USDFY, 2016FY, 2017

Revenue

22 m1.8 m

Cost of goods sold

2.3 m3.7 k

Gross profit

19.7 m1.8 m

Gross profit Margin, %

90%100%

R&D expense

8.9 m4.5 m

General and administrative expense

13 m11.2 m

Operating expense total

21.9 m15.7 m

EBIT

(2.2 m)(13.9 m)

EBIT margin, %

(10%)(767%)

Interest expense

14.9 m169 k

Interest income

169 k

Pre tax profit

(14.3 m)(17.8 m)

Income tax expense

4.1 m

Net Income

(14.3 m)74.9 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Revenue

1.1 m2.3 m2.1 m2.9 m4 m4.7 m5.4 m8.5 m580 k276.4 k818.6 k

Cost of goods sold

270.5 k807.9 k449.1 k332.7 k457.6 k534.9 k560.7 k921.8 k318 35.7 k

Gross profit

804.2 k1.4 m1.7 m2.5 m3.5 m4.2 m4.8 m7.6 m580 k276.1 k782.9 k

Gross profit Margin, %

75%64%79%88%89%89%90%89%100%100%96%

R&D expense

5.1 m4.2 m4 m2.3 m3.9 m2.7 m2.5 m1.3 m705.3 k999 k2.1 m

General and administrative expense

4.9 m2.6 m5.5 m4 m3.9 m4.1 m2.9 m2.9 m3 m1.8 m3.6 m

Operating expense total

10 m6.8 m9.5 m6.3 m7.8 m6.8 m5.4 m4.2 m3.7 m2.8 m5.7 m

EBIT

(9.2 m)(5.4 m)(7.8 m)(3.8 m)(4.3 m)(2.6 m)(580 k)3.4 m(3.1 m)(2.5 m)(4.9 m)

EBIT margin, %

(858%)(238%)(371%)(133%)(109%)(54%)(11%)40%(543%)(904%)(602%)

Interest expense

914.1 k920.9 k966.6 k1.6 m2.1 m2.2 m7.5 m2.6 m7.8 k

Interest income

5 k2.9 k31.4 k

Pre tax profit

(4.3 m)(6.7 m)(9.2 m)

Income tax expense

10.9 k

Net Income

(22 m)(28.9 m)(7.3 m)(17 m)(25.1 m)(3.7 m)(10.4 m)(10.4 m)85.6 m(6.7 m)(9.1 m)

Navidea Biopharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.9 m5.5 m7.2 m1.5 m2.8 m

Accounts Receivable

1.2 m816.5 k

Inventories

2.2 m1.5 m

Current Assets

37.3 m8.6 m12.6 m10.8 m13.8 m

PP&E

2.1 m2.5 m1.9 m1.3 m236.7 k

Total Assets

40.3 m11.9 m15 m12.5 m20.8 m

Accounts Payable

2.4 m1.5 m1.8 m7.1 m855 k

Short-term debt

Current Liabilities

11.3 m9.1 m6.2 m69.9 m8.1 m

Long-term debt

Total Liabilities

80.1 m8.7 m

Additional Paid-in Capital

313.1 m323 m326.1 m326.6 m331.1 m

Retained Earnings

(317.3 m)(353 m)(380.5 m)(394.9 m)(319.9 m)

Total Equity

12 m

Financial Leverage

1.7 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

17.5 m10.4 m4.9 m15.8 m11.4 m5.5 m1.2 m810.4 k13.4 m817 k4.7 m

Accounts Receivable

487.1 k1.5 m1.2 m1.8 m1.9 m

Inventories

1.9 m1.1 m571.6 k1.2 m877.2 k898.9 k769.8 k804.9 k748

Current Assets

20.6 m14 m8 m19.5 m15 m10 m6.9 m9.4 m21.7 m16.2 m6.6 m

PP&E

2.8 m2.6 m2.3 m2.2 m2.1 m1.8 m1.6 m1.4 m1.1 m206.1 k179.2 k

Total Assets

23.6 m17.6 m10.9 m22.2 m17.5 m12.3 m8.7 m11.2 m32.9 m18.3 m8.7 m

Accounts Payable

1.7 m2.4 m1.9 m1.4 m1.3 m2.9 m5.1 m4.9 m3.1 m700.2 k453.7 k

Short-term debt

2.3 m2.2 m

Current Liabilities

6.2 m8.3 m12.9 m5.6 m6.2 m57.1 m62.4 m63.8 m10 m12 m4.6 m

Long-term debt

2.3 m2.2 m

Total Debt

4.6 m4.4 m

Total Liabilities

13.4 m5.9 m

Additional Paid-in Capital

315.2 m314.7 m324.3 m324.7 m325.6 m326.4 m326.4 m326.6 m330.8 m331.5 m331.7 m

Retained Earnings

(339.2 m)(346.1 m)(360.3 m)(370 m)(378 m)(384.2 m)(390.9 m)(391 m)(309.3 m)(327.3 m)(329.7 m)

Total Equity

22.4 m4.9 m2.8 m

Financial Leverage

1.5 x3.7 x3.1 x

Navidea Biopharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(42.7 m)(35.7 m)(27.6 m)(14.3 m)74.9 m

Accounts Receivable

(1 m)334.1 k

Inventories

(1.9 m)761 k136 k(861.3 k)1.5 m

Accounts Payable

1 m(944.9 k)290 k5.4 m(6 m)

Cash From Operating Activities

(35.6 m)(29.1 m)(19.1 m)3.6 m59.1 m

Cash From Investing Activities

(1.3 m)(1.5 m)(27.8 k)(39.2 k)(1.8 m)

Short-term Borrowings

(6 m)(25 m)(30.3 m)(231.5 k)

Long-term Borrowings

(59.8 m)

Dividends Paid

Cash From Financing Activities

60.7 m3.2 m20.8 m(9.1 m)(56 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(22 m)(28.9 m)(7.3 m)(17 m)(25.1 m)(3.7 m)(10.4 m)(10.4 m)85.6 m(6.7 m)(9.1 m)

Depreciation and Amortization

235.4 k360.7 k149.8 k299.1 k431.4 k149.6 k267.4 k378.8 k86.5 k38 k75.5 k

Accounts Receivable

663.5 k(314.8 k)(394.5 k)(1 m)(1.1 m)903.1 k181.8 k210.5 k

Inventories

326.7 k573.2 k240.5 k(355.5 k)(83.7 k)(246 k)(116.9 k)(195.3 k)1.5 m

Accounts Payable

(748.3 k)(45.4 k)428.5 k(119.8 k)(178.6 k)1.1 m3.4 m3.2 m(3.8 m)(154.8 k)(401.3 k)

Cash From Operating Activities

(17.6 m)(24.3 m)(4.1 m)(10.8 m)(14.9 m)(1.7 m)(1.4 m)1.3 m66.3 m(2.3 m)8.3 m

Cash From Investing Activities

(1.1 m)(1.5 m)14.7 k(17.3 k)(19.2 k)(1.8 k)(39.2 k)(39.2 k)400 k996.8 k

Short-term Borrowings

(25 m)(25 m)(30 m)(30.3 m)(189.2 k)(189.2 k)(59.5 m)

Long-term Borrowings

(118.3 k)(237.9 k)

Cash From Financing Activities

3.2 m3.2 m3.5 m21.1 m20.8 m(693 )(4.6 m)(7.6 m)(54.4 m)(118.1 k)(7.4 m)

Navidea Biopharmaceuticals Ratios

USDY, 2018

EV/EBIT

-8.4 x

EV/CFO

5 x

Financial Leverage

3.1 x
Report incorrect company information